EMBRYOTROPIC PROPERTIES OF A NEW COMPOSITION OF FENBENDAZOLE AND ALBENDAZOLE (PANAVERM PLUS)

The drug Panaverm plus administered at the doses of 10,0; 15,0; 25,0; 35,0 and 45,0 mg/kg body weight (by 4.5 times increased dose) showed no embryotropic activity. Panaverm plus used at the dose of 55,0 mg / kg body weight did not cause changes in the development  of embryos, except  one case of hydrocephaly and reduction of embryo weight. Objective of research: studies of the embryotropic properties of preparation Panaverm plus. Materials and methods: The  studies of embryotropic properties of  preparation  Panaverm plus were conducted on 40 outbreed white female rats with weight 200-250 g. in accordance with «Methodical recommendations  for estimation  of drug effects on reproductive function of animals»  approved by Ministry of Healthcare of the Russian Federation (1997). Results and conclusion: Panaverm plus administered at the doses of 10,0; 15,0; 25,0; 35,0 and 45,0 mg/kg body weight (by 4.5 times increased dose) showed no embryotropic activity. Panaverm plus used at the dose of 55,0 mg / kg body weight did not cause changes in the development of embryos, except one case of hydrocephaly and reduction of embryo weight. 

1. Khabriev R. U. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniju novyh farmakologicheskih veshchestv [Handbook for experimental (pre-clinical) studies of new pharmacological compounds]. Moscow, 2005, 68 p.

2. Methodical recommendations for pre-clinical studies of reproductive toxicity of pharmacological preparations. Vedomosti Farmakologicheskogo Komiteta [Bulletin of Pharmacological Committee], 1998, no. 5, pp.13–20.